296 related articles for article (PubMed ID: 15098379)
1. [The role of raloxifene (Evista) in the treatment and prevention of postmenopausal osteoporosis].
Korsić M
Reumatizam; 2003; 50(2):55-7. PubMed ID: 15098379
[TBL] [Abstract][Full Text] [Related]
2. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
[TBL] [Abstract][Full Text] [Related]
3. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
Cranney A; Adachi JD
Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
[TBL] [Abstract][Full Text] [Related]
4. The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
Lee WL; Cheng MH; Tarng DC; Yang WC; Lee FK; Wang PH
J Chin Med Assoc; 2013 Jul; 76(7):365-71. PubMed ID: 23664736
[TBL] [Abstract][Full Text] [Related]
5. Raloxifene: a review of its use in postmenopausal osteoporosis.
Clemett D; Spencer CM
Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
[TBL] [Abstract][Full Text] [Related]
6. Prevention and treatment of osteoporosis in women with breast cancer.
Mincey BA; Moraghan TJ; Perez EA
Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
[TBL] [Abstract][Full Text] [Related]
7. [Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy].
Kobayashi H; Hamaya E
Nihon Yakurigaku Zasshi; 2005 Jan; 125(1):37-48. PubMed ID: 15738620
[No Abstract] [Full Text] [Related]
8. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
9. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for raloxifene use in daily clinical practice in the Swiss setting.
Lippuner K; Buchard PA; De Geyter C; Imthurn B; Lamy O; Litschgi M; Luzuy F; Schiessl K; Stute P; Birkhäuser M
Eur Spine J; 2012 Dec; 21(12):2407-17. PubMed ID: 22739699
[TBL] [Abstract][Full Text] [Related]
11. [Raloxifene - an unexploited possibility of prevention and treatment of postmenopausal osteoporosis].
Štěpán J; Rosa J; Pavelka K
Vnitr Lek; 2016; 62(10):781-788. PubMed ID: 27900864
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene for older women: a review of the literature.
Hansdóttir H
Clin Interv Aging; 2008; 3(1):45-50. PubMed ID: 18488877
[TBL] [Abstract][Full Text] [Related]
13. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
14. The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis.
Lufkin EG; Wong M; Deal C
Rheum Dis Clin North Am; 2001 Feb; 27(1):163-85, vii. PubMed ID: 11285993
[TBL] [Abstract][Full Text] [Related]
15. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation.
Siris E; Adachi JD; Lu Y; Fuerst T; Crans GG; Wong M; Harper KD; Genant HK
Osteoporos Int; 2002 Nov; 13(11):907-13. PubMed ID: 12415439
[TBL] [Abstract][Full Text] [Related]
16. Vertebral fractures: a hidden problem of osteoporosis.
Haczynski J; Jakimiuk A
Med Sci Monit; 2001; 7(5):1108-17. PubMed ID: 11535963
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of postmenopausal osteoporosis with raloxifene].
Fedelesova V; Chylova K; Dzurik
Bratisl Lek Listy; 2000; 101(9):527-8. PubMed ID: 11187059
[TBL] [Abstract][Full Text] [Related]
18. Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis.
Fontana A; Delmas PD
Endocrinol Metab Clin North Am; 2003 Mar; 32(1):219-32. PubMed ID: 12699300
[TBL] [Abstract][Full Text] [Related]
19. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Sambrook P
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
[TBL] [Abstract][Full Text] [Related]
20. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]